Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tailors blood pressure drugs, outsmarting One-Size-Fits-All medicine

NCT ID NCT04223934

Disease control Sponsor: Optima Integrated Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence system called optima4BP can improve blood pressure control in people with hypertension. The AI analyzes a patient's medications and recommends the best drug adjustments—adding, removing, replacing, or changing doses. Researchers will compare the AI-guided approach to standard care over six months, measuring blood pressure changes and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an artificial intelligence clinical decision support system called optima4BP that recommends blood pressure medication adjustments
What this could lead to
If successful, this AI tool could help doctors personalize hypertension treatment more effectively, potentially lowering blood pressure and reducing heart risks.
What could go wrong
This is a relatively small study, and the AI recommendations still require doctor approval. The tool may not work for everyone or may lead to more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

165 people

The number who actually took part.

Started

Feb 2020

Finished

Jun 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Two or more blood pressure (BP) readings of ≥ 140/90 mmHg during UCSF primary care or cardiology office visits within the last 12 months * Therapy with medications from at least 1 anti-HTN pharmacological agents at the time of the last office visit * At least minimally "tech-savvy" defined as Ownership of a compatible smartphone and Ability to access the internet * Active Electronic Health Record MyChart account Exclusion Criteria: * Home anti-HTN medication therapy doesn't match the electronic health record medication list * Anti-HTN medication therapy changed within 30 days prior to enrollment * Inability to operate a BP cuff * Incompatible smartphone device (Galaxy S5 Android 5.0) * Less than minimally "tech-savvy" defined as Inability to use the Internet * Non-compliance with medical follow-up (\>3 "no shows" in the previous 12 months) * Planned coronary revascularization in the next 12 months * Myocardial infarction, coronary revascularization, stroke, cardiac or aortic surgery in the previous 90 days * GFR \< 30 (CKD stage IV/ V) * Treating physician rules out the patient due to superseding health management concerns * Treating physician rules out the patient due to other concerns

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • University of California San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.